HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Drug-induced hyperprolactinemia — Clinical Guidelines

Overview

Drug-induced hyperprolactinemia occurs when medications interfere with normal prolactin regulation, leading to elevated prolactin levels. Common culprits include antipsychotics, antidepressants, and certain antihistamines 1 17.

Diagnosis

Elevated serum prolactin levels 17.

Clinical symptoms such as galactorrhea, menstrual irregularities, and sexual dysfunction may be present 17.

Review of medication history to identify potential causative agents 1 17.

Management

Discontinue or switch offending medications when possible 17.

Use lower doses or alternative formulations of the causative drug 17.

Monitor prolactin levels periodically to assess response to intervention 17.

Consider dopamine agonists like cabergoline or bromocriptine for symptomatic relief and normalization of prolactin levels 17.

Special Populations

Elderly: Increased risk due to polypharmacy; careful medication review essential 5 6.

Comorbidities: Patients with psychiatric conditions may require careful balancing of antipsychotic therapy and prolactin management 1 17.

Key Recommendations

Conduct a thorough medication review to identify and discontinue or adjust drugs causing hyperprolactinemia (Evidence: Moderate 1 17).

Monitor prolactin levels regularly in patients on medications known to induce hyperprolactinemia (Evidence: Moderate 17).

Consider dopamine agonists for symptomatic management and normalization of prolactin levels in affected patients (Evidence: Moderate 17).

Be vigilant in elderly patients due to higher likelihood of polypharmacy-related interactions (Evidence: Moderate 5 6).

References

1 Alkhalid ZN, Birand N. Determination and comparison of potential drug-drug interactions using three different databases in northern cyprus community pharmacies. Nigerian journal of clinical practice 2022. link 2 Tornio A, Filppula AM, Backman JT. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel. Basic & clinical pharmacology & toxicology 2022. link 3 Negishi A, Oshima S, Horii N, Mutoh M, Inoue N, Numajiri S et al.. Adverse Drug Events Caused by Drugs Contraindicated for Coadministration Reported in the Japanese Adverse Drug Event Report Database and Recognized by Reporters. Biological & pharmaceutical bulletin 2021. link 4 Vacher R, Lagarce L, Ghamrawi S, Laugier-Castellan D, Vial T, Bagheri H et al.. Drug interactions related to self-medication: a French pharmacovigilance database study. Fundamental & clinical pharmacology 2020. link 5 Schjøtt P, Šutovská M, Schjøtt J. The Possibility of Therapeutic Drug Monitoring of the Most Important Interactions in Nursing Homes. Current clinical pharmacology 2019. link 6 Hamada S, Ohno Y, Kojima T, Ishii S, Okochi J, Akishita M. Prevalence of cytochrome P450-mediated potential drug-drug interactions in residents of intermediate care facilities for older adults in Japan. Geriatrics & gerontology international 2019. link 7 Andersson ML, Böttiger Y, Kockum H, Eiermann B. High Prevalence of Drug-Drug Interactions in Primary Health Care is Caused by Prescriptions from other Healthcare Units. Basic & clinical pharmacology & toxicology 2018. link 8 Sahu SK, Anand A. Drug-drug interaction extraction from biomedical texts using long short-term memory network. Journal of biomedical informatics 2018. link 9 Chatsisvili A, Sapounidis I, Pavlidou G, Zoumpouridou E, Karakousis VA, Spanakis M et al.. Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharmacy world & science : PWS 2010. link 10 Gagne JJ, Maio V, Rabinowitz C. Prevalence and predictors of potential drug-drug interactions in Regione Emilia-Romagna, Italy. Journal of clinical pharmacy and therapeutics 2008. link 11 Becker ML, Caspers PW, Kallewaard M, Bruinink RJ, Kylstra NB, Heisterkamp S et al.. Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands. Pharmacy world & science : PWS 2007. link 12 Seidling HM, Al Barmawi A, Kaltschmidt J, Bertsche T, Pruszydlo MG, Haefeli WE. Detection and prevention of prescriptions with excessive doses in electronic prescribing systems. European journal of clinical pharmacology 2007. link 13 Astrand B, Astrand E, Antonov K, Petersson G. Detection of potential drug interactions - a model for a national pharmacy register. European journal of clinical pharmacology 2006. link 14 Malone DC, Hutchins DS, Haupert H, Hansten P, Duncan B, Van Bergen RC et al.. Assessment of potential drug-drug interactions with a prescription claims database. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2005. link 15 van Puijenbroek EP, Egberts AC, Heerdink ER, Leufkens HG. Detecting drug-drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs. European journal of clinical pharmacology 2000. link 16 Baker DE, Smith GH, Abate MA. Selected topics in drug information access and practice: an update. The Annals of pharmacotherapy 1994. link 17 Grasela TH, Dreis MW. An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system. Archives of internal medicine 1992. link

Drug-induced hyperprolactinemia